BioSpace News Archive

Dixie Brands, Inc. (Dixie) announced that it has obtained conditional approval on November 13, 2018 from the Canadian Securities Exchange (the CSE) for the listing of the shares that will result from Dixie’s completion of a reverse takeover (RTO) of a Canadian public company, Academy Explorations Limited (Academy) which will be renamed Dixie Brands Inc. on completion of the RTO. The common shares of the resulting reporting issuer would then be listed for trading on the CSE.

Lupus Foundation of America hosts Annual Evening of Hope Gala in New York City

Leading data, technology, and service providers help life sciences organizations extend the value of their customer reference data

Prime Healthcare Doubles the Number of Hospitals Awarded

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, announced today its reported results for the third quarter 2018.

CannTrust Holdings Inc. today announced financial and operating results for the three and nine months ending September 30, 2018.

LexisNexis® Risk Solutions, a pioneer in the social determinants of health (SDOH) arena will participate in a key thought-leader panel discussion, “Beyond Risk Adjustment: The Role of Quality Measurement in Improving Access and Reducing Disparities,”

The U.S. Agency for International Development (USAID), Land O’Lakes International Development, and the Foundation for Food and Agriculture Research (FFAR) announced the six winners of the Feed the Future Fall Armyworm Tech Prize at the AfricaCom conference in South Africa today.

CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $24.50 per share.

Concept Life Sciences (“Concept”), the integrated drug discovery and development and analytical services company, today announced the expansion of its regulatory GLP (good laboratory practice) capabilities at the Group’s Dundee and Bradford sites.